Granules India, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. The company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain - from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).

Over the years, the company has evolved itself from being an API manufacturer to a company that has a strong presence across the value chain. Cost efficiencies and continuous innovation continue to remain a core focus for the company that it strives to achieve through innovation at the development stage, ongoing continuous improvements and through various strategies across supply chain and manufacturing.

The company’s R&D capabilities come from the core value of ‘Innovation’, that drives the scientific teams to achieve efficient processes in API and robust Finished Dosage that meet global regulatory standards. It has emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.

Business area of the company

Granules India is a vertically integrated pharmaceutical company with a presence across the entire value chain - from Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs) to Finished Dosages (FDs). The company’s differentiated business model, combining scale, cost leadership, and regulatory compliance, allows it to serve customers across several countries. The company’s manufacturing footprint spans India and the United States, supported by global R&D centres and a growing innovation pipeline.

Products of the company

• Active Pharmaceutical Ingredients
• Pharmaceutical Formulations Intermediates
• Finished Dosages

• Declared the Best Manufacturer of Bulk Drugs at the HMTV Business Excellence Awards
• Recognized at the Emerging Supplier of the Year at the Rising Star Award
• Received Certificate of Appreciataion from the Telangana government recognising the relief work the company extended during the pandemic
• Won Silver at the India Green Manufacturing Challenge
• API unit-1 won Gold and was given a certification for efforts in the reduction of effluent generation at source at the 11th CII National 3M competition 2021
• API unit-2 won Silver at the 11th CII National 3M competition 2021 for low-cost automation through an interlock between universal Mill & Screw Feeder to enhance effective equipment utilization
• Won the 2nd TPM Challengers Trophy as Jury Challenger for efforts in the reduction of effluent generation at source
• At the 10th CII National PokaYoke Competition, the gold and silver winner for reduction of tablet defects due to oil spots and elimination of human intervention during fluid bed drying, respectively at the GGP Awards

• IGBC Green Crusader
• Best Skill Development Initiative (Pharma) - TISS Leap Vault CLO Awards 2022
• Gold Winner at the 10th CII National Poka-Yoke Competition
• Silver Winner at the 10th CII National Poka-Yoke Competition
• As one of the Most Trusted Brands Most Trusted Brands of India 2023
• Best Manufacturer Bulk Drug- Business Excellence Award

• BW Healthcare World 40 Under 40 Young Achievers 2023 Initiated by Businessworld
• Excellence in QMS Integration Award & Quality Culture Transformation (Plant) Award
• The Repharma Awards for Excellence in Contribution Towards Sustainability Initiative of ET Pharma and ET Healthworld
• IGBC Green Crusader Award for registering their project Granules Life Sciences Initiated by the Indian Green Building Council, Confederation of Indian Industry (CII)
• FDD Leadership Award 2023 – Formulation Development and Drug Delivery Organized by Express Pharma and the Indian Express Pvt. Ltd.
• Future Ready Organization Award An initiative by Economic Times

• BW PharmaWorld Person of the Year Award 2024
• Exemplary Leadership in Social Impact & Corporate Responsibility Award
• Golden Peacock Awards – Winner of Sustainability 2024
• Best Management Award 2025
• Gold Medal at Red Cross Annual General Meeting
• Economic Times RE Pharma Award
• CII CFO Excellence Award for the Pharma and Chemicals sector
• Silver Award at CII SR-EHS Excellence Awards 2024
• 49th CII National Kaizen Competition
• CII 25th National Award for Excellence in Energy Management 2024
• Valued Partner of Ashray Akruti

Milestones

• 1984: Formed Triton Laboratories to produce Paracetamol API at its Bonthapally facility in Hyderabad.
• 1990: Opened Triton’s second manufacturing facility at Jeedimetla to produce multiple APIs.
• 1991: Incorporated Granules India Private Limited.
• 1993: Established its first PFI facility at Jeedimetla.
• 1995: Became a listed company following an IPO at the Hyderabad Stock Exchange.
• 2003: Set up a new largevolume PFI facility in Gagillapur.
• 2003: Set up whollyowned subsidiary, Granules USA, for marketing in the US.
• 2005: Built a new Paracetamol plant in Bonthapally, Hyderabad.
• 2008: Entered the Finished Dosages segment.
• 2010: Received US FDA approval for its first Abbreviated New Drug Application (ANDA).
• 2013: Established API R&D facility in Pragathi Nagar.
• 2013: Acquired Auctus Pharma – an API manufacturing facility with regulatory approvals.
• 2014: Set up a whollyowned subsidiary in the US. Granules Pharmaceuticals began focusing on formulation R&D to forward integrate APIs.
• 2015: Laid the foundation for its Oncology API and OSD plant and a multiple product API plant in Visakhapatnam.
• 2019: Entered the frontend business for the sale of Rx Products in the US under the GPI label.
• 2021: Set up the largest single manufacturing site for a multiunit pellet system facility at Gagillapur.
• 2023: Set up GPAK, an around 80,000 sq. ft. packaging facility with four packaging suites and a warehousing facility.
• 2023: Established new purpose, mission and values.
• 2024: Granules Life Sciences (GLS), with a planned FD capacity of 10 bn dosages, successfully commenced operations.
• 2024: Granules CZRO pilot plant commenced operations.
• 2025: Successfully acquired Switzerland’s peptide CDMO firm Senn Chemicals AG.
• 2025: Inaugurated phase-II of GLS expanding dosage capacity to 10 billion dosages.